B7-H1 antibodies and method of use

• US 8,460,927 B2
• Filed: 10/25/2011
• Issued: 06/11/2013
• Est. Priority Date: 11/30/1999
• Status: Expired due to Fees

• Current Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Original Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Inventors: Chen, Lieping
• Primary Examiner(s): OUSPENSKI, ILIA I
• Application Number:
  US13/280,779
• Publication Number:
  US 20120064626A1
• Time in Patent Office: 595 Days
• Field of Search: None
• US Class Current: 435/375
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 14/70532 B7 molecules, e.g. CD80, CD86
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/2827 against B7 molecules, e.g. CD80, CD86
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/524 CH2 domain
• CPC Class Codes: C07K 2317/526 CH3 domain
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2319/74 containing a fusion for binding to a cell surface receptor
• CPC Class Codes: G01N 2333/70532 B7 molecules, e.g. CD80, CD86
• CPC Class Codes: G01N 33/502 for testing non-proliferative effects
• CPC Class Codes: G01N 33/505 involving T-cells

Abstract

The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides.

Claims

1. A method for inhibiting a co-stimulatory effect of B7-H1 on T-cells, comprising:

contacting said B7-H1 with an isolated antibody that binds specifically to a B7-H1 polypeptide which comprises

(a) amino acids having the sequence set forth in SEQ ID NO;

1;

or

(b) amino acids that are encoded by a polynucleotide comprising nucleotides having the sequence set forth in SEQ ID NO;

2,

wherein the contacting comprises culturing the antibody with the T-cell in vitro, to thereby inhibit a co-stimulatory effect of B7-H1 on T-cells.

2. An isolated antibody that binds specifically to a B7-H1 polypeptide which comprises

(a) amino acids having the sequence set forth in SEQ ID NO:

3;

or

(b) amino acids that are encoded by a polynucleotide comprising nucleotides having the sequence set forth in SEQ ID NO;

4.

4. An isolated antibody according to claim 2 that binds specifically to the polypeptide comprising amino acids having the sequence set forth in SEQ ID NO:

16.

3. An antibody fragment that binds specifically to a B7-H1 polypeptide which comprises

(a) amino acids having the sequence set forth in SEQ ID NO:

3;

or

(b) amino acids that are encoded by a polynucleotide comprising nucleotides having the sequence set forth in SEQ ID NO;

4.

5. An isolated antibody fragment according to claim 3 that binds specifically to the polypeptide comprising amino acids having the sequence set forth in SEQ ID NO:

16.

6. A method for inhibiting a co-stimulatory effect of B7-H1 on T-cells, comprising:

contacting said B7-H1 with an isolated antibody or an antigen binding fragment thereof which binds specifically to a soluble B7-H1 polypeptide which is not membrane-bound, wherein said soluble B7-H1 polypeptide comprises amino acid domain(s) having the sequence(s) shown in FIG. 2A (SEQ ID NO;

1) such that the polypeptide is soluble, to thereby inhibit a co-stimulatory effect of B7-H1 on T-cells.